Nations Financial Group Inc. IA ADV Has $676,000 Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)

Nations Financial Group Inc. IA ADV grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 36.9% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 12,919 shares of the biopharmaceutical company’s stock after buying an additional 3,480 shares during the quarter. Nations Financial Group Inc. IA ADV’s holdings in Halozyme Therapeutics were worth $676,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the company. Vanguard Group Inc. lifted its holdings in shares of Halozyme Therapeutics by 1.2% during the 4th quarter. Vanguard Group Inc. now owns 13,259,514 shares of the biopharmaceutical company’s stock valued at $490,072,000 after buying an additional 152,870 shares during the last quarter. TD Asset Management Inc raised its stake in shares of Halozyme Therapeutics by 28.1% in the 1st quarter. TD Asset Management Inc now owns 2,541,266 shares of the biopharmaceutical company’s stock valued at $103,379,000 after acquiring an additional 557,350 shares in the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Halozyme Therapeutics by 2.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,736,122 shares of the biopharmaceutical company’s stock valued at $64,167,000 after acquiring an additional 37,763 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of Halozyme Therapeutics by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,613,113 shares of the biopharmaceutical company’s stock valued at $59,622,000 after acquiring an additional 145,879 shares in the last quarter. Finally, Stephens Investment Management Group LLC raised its stake in shares of Halozyme Therapeutics by 4.4% in the 4th quarter. Stephens Investment Management Group LLC now owns 1,518,455 shares of the biopharmaceutical company’s stock valued at $56,122,000 after acquiring an additional 63,748 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Halozyme Therapeutics Stock Performance

HALO opened at $63.85 on Friday. The stock has a market cap of $8.13 billion, a PE ratio of 26.38, a P/E/G ratio of 0.56 and a beta of 1.27. The company has a current ratio of 6.64, a quick ratio of 5.36 and a debt-to-equity ratio of 8.44. Halozyme Therapeutics, Inc. has a 1 year low of $32.83 and a 1 year high of $65.53. The stock’s 50 day simple moving average is $55.79 and its 200-day simple moving average is $46.78.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The business had revenue of $231.40 million for the quarter, compared to analysts’ expectations of $204.94 million. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. Halozyme Therapeutics’s quarterly revenue was up 4.7% on a year-over-year basis. During the same period in the previous year, the business posted $0.68 earnings per share. Sell-side analysts forecast that Halozyme Therapeutics, Inc. will post 3.66 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on HALO. The Goldman Sachs Group raised their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a research note on Monday, July 22nd. Piper Sandler downgraded Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and raised their price objective for the company from $48.00 to $51.00 in a research note on Friday, June 7th. HC Wainwright reaffirmed a “buy” rating and issued a $65.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. TD Cowen lifted their price target on Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research report on Wednesday, August 7th. Finally, JMP Securities dropped their price target on Halozyme Therapeutics from $72.00 to $71.00 and set a “market outperform” rating on the stock in a research report on Wednesday, May 8th. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $59.44.

Insider Activity at Halozyme Therapeutics

In related news, Director Matthew L. Posard sold 10,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the sale, the director now owns 109,755 shares of the company’s stock, valued at approximately $5,488,847.55. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other Halozyme Therapeutics news, Director Matthew L. Posard sold 10,000 shares of the business’s stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now owns 109,755 shares of the company’s stock, valued at $5,488,847.55. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Nicole Labrosse sold 5,000 shares of the business’s stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $53.93, for a total value of $269,650.00. Following the completion of the transaction, the chief financial officer now directly owns 15,480 shares in the company, valued at approximately $834,836.40. The disclosure for this sale can be found here. Insiders have sold a total of 64,881 shares of company stock valued at $3,585,084 in the last 90 days. 2.40% of the stock is owned by corporate insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.